Frontlight ResearchEarly access
CompletedPhase 2
Epirubicin for the Treatment of Sepsis & Septic Shock
Key facts
- Who runs it
- Friedrich-Schiller-Universitaet Jena
- Where
- Germany5 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 45 people enrolled
- Started
- 30 Jun 2022
- Ended
- 21 May 2025
- Type of study
- Interventional
- Record updated
- 1 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Written informed consent of subject or its authorized representative or legal representative or confirmation of the urgency of participation in the clinical trial and the possible benefit to the subject by an independent consultant or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent
- Patients >18 years with sepsis or septic shock, currently hospitalized at the ICU or IMC regardless where the sepsis was first diagnosed
- Sepsis diagnosis, as currently defined, within 48 hours prior to screening regardless of site of infection
Who cannot take part
- Concomitant medication with Verapamil or Cimetidine
- Prior enrollment in this study
- Immunosuppressive therapy
- Acute severe infection within 4 weeks prior to admission (Hospitalization for an infection or in case of hospital acquired infection transfer to a higher level of care due to the infection)
- Ongoing or History of chemotherapy
- Hypersensitivity to epirubicin
- History of bone marrow or solid organ transplantation
- Chronic infection
- Leukopenia/Neutropenia/Thrombocytopenia-prior or upon inclusion (Leukocyte Count <4,000/µL; Neutrophil/Thrombocyte Count below Lower Limit of Normal)
- Acute liver failure following the European Association for the Study of the Liver definition as International Normalized Ratio (INR) >1.5 and elevation of transaminases >= 3 times of the upper normal limit (European Association for the Study of the Liver. Electronic address et al., 2017)
- Cardiomyopathy with a documented ejection fraction <30% or ICD implantation
- Pregnancy during all trimester/breast-feeding
- Chronic mechanical ventilation dependency
- Cystic fibrosis
- Participation in another clinical intervention trial
- Weight >135 kg/BMI >45
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess safety of low-dose epirubicin as an adjunctive therapy for patients with sepsis and septic shock.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 1 October 2024